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CHAPTER 1: INTRODUCTION
1.1. Methamphetamine (METH)
1.1.1. History of METH Use
Methamphetamine (METH) is a methylated amphetamine (Chemical structures are
presented in Figure 1.1) with psychostimulant properties. Amphetamine was synthesized
in Germany in 1887 by Romanian chemist Lazăr Edeleanu, while METH was synthesized
in 1893 by Japanese scientist Nagai Nagayoshi. Akira Ogata used iodine and red
phosphorous synthesized crystallized METH in 1919. They provided the basis for
production of the drug on a larger scale [1]. Amphetamine and METH were first used to
help with respiratory problems and nasal congestion respectively. Thereafter, METH
quickly became a popular medication during the 1940s and 1950s. During World War II,
METH was used to help the soldiers stay alert. Abuse of the drug reached its peak in the
1960s. Following this, the Drug Abuse Control Amendments of 1965 and the
Comprehensive Drug Abuse Prevention and Control Act of 1970 restricted the use of
METH, and it was classified as a Schedule II drug [2]. In the 1980s, a crystalline form of
METH that could be smoked, called “ice”, began to be imported from Asia to Hawaii
[3]. This highly addictive form of METH quickly found its way to the U.S. West Coast and
slowly began working its way east. By 1990, METH had replaced cocaine as the stimulant
of choice among drug users in many areas of California [4]. With increasing numbers of
large-scale manufacturers in Mexico and other parts of the world, METH continues to be
a significant problem in the U.S. Today METH can only be prescribed for Attention Deficit
Hyperactivity Disorder, extreme obesity, and narcolepsy. According to the Substance

2
Abuse and Mental Health Services Administration report, the number of patients treated
for METH abuse increased by 50 percent in 2014 compared to 2009. The United Nations
Office on Drugs and Crime reported that the amount of METH seized worldwide has
increased by 158 percent during the last five years [5]. According to the World Drug Report
2015 (United Nations Office on Drugs and Crime 2015), North America continues to be
one of the major consumers and producers of METH worldwide. This indicates that METH
abuse should be considered a serious public health problem in the United States.
1.1.2. Properties of METH
METH comes in a variety of forms, such as a pure crystalline hydrochloride salt
and formulated tablets. Routes of administration include intravenous injection, smoking,
oral ingestion, and intranasal sniffing [6, 7]. Smoking is the most common route of
administration. When smoked or injected, METH produces an intensely pleasurable initial
rush that lasts only a few minutes, followed by an extended period of euphoria [8].
METH is a synthetic stimulant that affects the brain and central nervous system
(CNS) [9]. It stimulates the release of dopamine (DA), serotonin (5-HT) and
norepinephrine, and blocks their reuptake [10]. The presence of a large amount of these
neurotransmitters in the synapses produces sensations of euphoria, feelings of invincibility,
increased wakefulness, heightened sexual experiences, and hyperactivity that results from
increased energy for extended periods of time. Deleterious short-term effects include rapid
pulse, shallow breathing, hyperthermia, decreased appetite, increased respiration,
confusion, irritability, chest pain, hypertension, convulsions, anxiety, aggressiveness, and
symptoms of psychosis such as paranoia and hallucinations [11, 12]. This period is
followed by mental and physical exhaustion, dizziness, reduced concentration, hunger,
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decreased energy, and a desire for more METH [1]. Cognitive impairments and changes in
the brain that result in symptoms similar to those of Parkinson's disease may occur [13].
Long-term use of METH is associated with neurotoxicity manifested as psychosis, anxiety,
cognitive impairments, psychological dependence, and clinical depression that may lead to
homicidal and suicidal ideation and action [8]. The medical use of METH is now confined
to circumstances such as obesity, Attention Deficit Hyperactivity Disorder and narcolepsy
[14].

Figure 1.1. Chemical structures of amphetamine (left) and METH (right).
(pubchem.ncbi.nlm.nih.gov).
1.1.3. Molecular Mechanism Underlying METH Abuse
Deep within the brain is a set of structures called the limbic system. It contains the
brain’s reward circuit, which controls and regulates our ability to feel pleasure [15]. Feeling
pleasure is the primary motivation for humans to repeat drug-taking behavior. When the
reward circuit is activated, each individual cell in the circuit produces chemical and
electrical signals [16]. After METH administration, the drug quickly enters the brain.
METH facilitates the release of the catecholamines DA, 5-HT, and noradrenaline from
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nerve terminals in the brain, and inhibits their uptake. This leads to an increase in the
synaptic concentration of these neurotransmitters and results in increased stimulation of
postsynaptic receptors. To induce pleasurable effects, DA neurons release the
neurotransmitter DA in the reward circuit. The released DA acts on DA receptors and
actives a downstream signal. When a reward is encountered, the pre-synaptic cell releases
a large amount of DA in a sudden burst. The excess of DA in the synaptic cleft is removed
by DA transporters (DATs). Higher doses of METH can profoundly increase the release of
DA from a neuron leading to high DA levels in the synapse where it becomes trapped since
METH prevents the transporters from removing it [17]. The post-synaptic cell is activated
to dangerously high levels because DA remains in the synapse, which causes powerful
feelings of euphoria and makes METH incredibly addictive.
1.2. METH Neurotoxicity
METH can cause neurotoxicity. The Interagency Committee on Neurotoxicology
defines neurotoxicity as permanent and reversible effects on the structure or function of the
nervous system that can cause at least one of the following: loss of the neuronal
components (e.g. synthesizing enzymes, receptors, transporters); a loss of the entire neuron
and components therein (degeneration); histological signs of neuronal damage (silver
staining, gliosis, swollen axons); and a persistent behavioral abnormality associated with
the drug. This definition encompasses neuronal dysfunction in addition to degeneration,
which is usually equalized with the term neurotoxicity. The established molecular
mechanisms involved in mediating METH neurotoxicity include monoamine terminal
(DAergic and 5HTergic) damage, mitochondrial dysfunction, hyperthermia, inflammation,
excitotoxicity, and oxidative stress.
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Hyperthermia occurs after the administration of high doses of METH [18, 19], and
its occurrence is important for the development of METH neurotoxicity in DA and 5-HT
terminals. For instance, in mice, multiple injections of high-dose METH at room
temperature produced a significant depletion of DA in the striatum; however, equivalent
doses of METH administered in a cold environment blocked striatal DA and 5-HT
depletions [20]. Hyperthermia by itself does not decrease striatal DA levels in rodents [21].
Hyperthermia might interact with other known mediators of METH neurotoxicity, such as
increased glutamate (GLU) neurotransmission and oxidative stress [22]. For example,
inhibition of METH-induced hyperthermia decreases the formation of reactive oxygen
species (ROS) in the striatum that, in turn, attenuates the damage to DA terminals [23].
1.2.1. METH Effects on Catecholaminergic Neuronal Terminals
METH treatment can cause acute increases in both DA and 5-HT release, because
of the action of the drug on DAT and 5-HT transporters (SERT). METH is known to be a
substrate for both transporters and is transported into the axon terminal [24, 25]. After its
intracellular transport (transporter- or diffusion-mediated) into the terminal, METH
disrupts the storage vesicle proton gradient and causes the release of DA and 5-HT from
vesicular compartments into the cytoplasm [26]. Cytoplasmic monoamine concentrations
and DA release can be affected by METH via alteration of the function of the vesicular
monoamine transporter (VMAT-2) [27, 28]. The directionality of the DA and 5-HT
transporters can be reversed by increasing cytoplasmic DA and 5-HT levels, and causes
significant, action potential-independent neurotransmitter efflux [29]. Short-term
decreases in neurotransmitter reuptake also contribute to increases in extracellular DA
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levels [30]. In addition, METH causes acute increases in striatal GLU levels via D1
receptor-mediated disinhibition of corticostriatal GLU release [31].
Binge METH administration is an established drug regimen causing neurotoxicity
that includes degeneration of DAergic and 5-HTergic terminals in the striatum,
hippocampus, and prefrontal cortex of experimental animals [32, 33]. Acute effects of
METH include persistent DA and 5-HT terminal damage, manifested by long-term
decreases in DAergic and 5-HTergic markers, in the striatum, hippocampus, and prefrontal
cortex [32, 33]. The damage associated with METH has been shown to persist for at least
two years in rodents and non-human primates [34, 35]. The expression of certain
neurochemical markers, such as tryptophan hydroxylase and tyrosine hydroxylase, which
are the rate-limiting enzymes for 5-HT and DA respectively, decreases after METH
treatment. There is also a decrease in DAT and SERT expression [33, 36]. Excepting tissue
content and neurotransmitter proteins, histological signs of neuronal damage have been
reported which include the presence of swollen and distorted nerve terminals [37, 38].
Chronic administration of high METH doses also leads to neurotoxicity. Long-term METH
abuse, which can damage DA and 5-HT nerve terminals, is associated with deficits in
neuropsychological test performance, and it has been estimated that 40% of METH users
display abnormalities on neuropsychiatric tests [39]. Chronic METH exposure converges
to produce neuronal damage and inflammation [20]. A persistent reduction in most DA
markers [13, 40] and SERT [41] has also been observed in human chronic METH users.
1.2.2. METH and Neuronal Apoptosis
There is some supporting evidence indicating that METH may induce apoptosis or
even cell death in some neuronal populations, in addition to damaging DA and 5-HT
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terminals [42]. Apoptosis is a cell suicide program that is initiated after exposure to
cytotoxic stressors, including UV, IR irradiation, chemotherapeutic drugs, and hypoxia.
The marker for apoptotic cell death, Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL), increases in the striatum after exposure to METH [42, 43]. Importantly,
METH administration affects brain functions, such as long-term memory, integrative
functions, and attention [44], conditions which reflect hippocampal degeneration. The
hippocampus is an important area in the temporal lobe of the brain. It plays a role in
cognitive function including short-term memory, motivation, and emotional responses.
Hippocampal degeneration has been observed in animals after exposure to high-dose
METH [45]. METH-induced cell death was reported in the cortex, hippocampus, and
hippocampal remnants [46]. Some papers have demonstrated cell death of calbindincontaining GABA interneurons within the hippocampus in animal models [45, 47]. In the
striatum, METH causes apoptosis in neurons post-synaptic to striatal monoaminergic
terminals [46, 48, 49]. The apoptotic cells have been identified in subpopulations of
GABA-interneurons, such al parvalbumin-containing striatal GABA interneurons [44].
METH-induced apoptosis in neuronal cell bodies is associated with mitochondrial damage
and endoplasmic reticulum stress [42]. At the same time, METH causes DNA damage and
alterations in the expression of Bcl-2 related genes, which may contribute to cell death in
GABA interneurons [50]. METH can also induce apoptosis through increases in caspase3 activity and the Fas/FasL cell death pathway [51].
1.2.3. METH and Inflammatory Response
METH has been reported to trigger inflammatory responses in areas where DA and
5-HT terminals are damaged. METH elicits microglial activation in rat and mouse striati
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[52, 53], rat cortices (including somatosensory and frontal cortices) [45, 54] and
hippocampi [55]. Moreover, METH can trigger the release of some pro-inflammatory
cytokines, which can lead to glial dysfunction as well as neuronal death [55, 56]. METH
also induces reactive gliosis supported by the observation of increased glial fibrillary
acidic protein (GFAP) immunoreactivity in the striatum [57], hippocampus, and indusium
griseum [58]. Reactive gliosis is considered to be a universal reaction of injury in the CNS
and is used as a specific marker of neuronal damage.
METH-induced release of GLU also contributes to the activation of inflammatory
mediators which enhance the METH toxicity to monoaminergic as well as nonmonoaminergic neurons [20]. For instance, GLU receptor activation is known to stimulate
microglial activation whereas GLU antagonism suppresses the appearance of microglial
activation [59]. Furthermore, during METH exposure, microglial activation and increases
in GLU are seen in the striatum, prefrontal cortex, and hippocampus [60].
1.2.4. METH and Oxidative Stress
Reactive oxygen species are produced following METH exposure through
numerous mechanisms. When cytoplasmic DA increases following exposure to
pharmacologically relevant METH levels [61], DA-dependent oxidative stress has been
observed due to DA autoxidation [62]. Dopamine can also cause oxidative stress via its
metabolism by monoamine oxidase (MAO) which can induce the generation of superoxide
and hydrogen peroxide free radicals [63]. Hydrogen peroxide can react with iron via the
Fenton reaction and generate hydroxyl radicals, which are highly reactive and can result in
damage by causing DNA mutations, lipid peroxidation, and modification of certain amino
acids [64]. Damage to lipids and proteins causes DAergic terminal loss. Moreover, METH
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exposure can cause oxidative stress because it can increase nitric oxide synthase activity
and consequently increase the reactive nitrogen species [65]. Impairment of mitochondrial
function has also been linked to pathways generating ROS, which can lead to an oxidized
environment and decreased ATP production [66]. Oxidative stress can be further enhanced
by dysfunction of antioxidant enzymes [67]. Enzymatic antioxidant defenses (e.g. catalase,
superoxide peroxidases, and enzymes of the glutathione antioxidant system) serve to
counterbalance the effect of oxidants such as hydrogen peroxide, hydroxyl radical, and
superoxide radical. The activity of glutathione peroxidase (GPx) depends on the
availability of reduced glutathione (GSH), which is the most important non-enzymatic
antioxidant [68]. Antioxidant treatments have been shown to be neuroprotective against
the damage produced by METH. This finding substantiates the significant contribution of
oxidative stress to the neurotoxicity of amphetamines [69].
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Figure 1.2. Oxidative stress in METH toxicity. As high levels of METH enter the
DAergic terminal, DA is released from storage vesicles, and triggers the generation of
many reactive oxygen species (ROS). High-dose METH also enhances the release of
glutamate in the striatum, leading to excitotoxicity. The generation of ROS and
excitotoxicity can increase the oxidative stress, which enhances the METH-induced
neurotoxicity.
1.2.4. Markers for Apoptosis and Oxidative Stress
Apoptosis is a programmed cell death. Caspases are the central mediators of this
process. In mammals, caspases involved in apoptotic responses are classified into two
groups according to their function and structure. The first group is termed initiator caspases
(caspase-2, 8, 9, 10) that contain N-terminal adapter domains that allow for auto-cleavage
and activation of downstream caspases. The second group is termed effector or executioner
caspases (caspase-3, 6, 7) that lack of N-terminal adapter domains and are cleaved and
activated by initiator caspases [70]. Caspases-3 and 7 are critical mediators of
mitochondrial dysfunction-mediated apoptosis. For example, they can amplify the initial
death signal by promoting cytochrome c release [71]. Under intrinsic stress, cleaved
caspase-3 is produced via cleavage of caspase-9, which is considered to be the marker of
middle stage apoptosis.
Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme, has a particularly wellresearched role in base excision repair [72]. In addition to being involved in DNA repair,
PARP is also directly involved in both apoptosis and necrosis [73, 74]. Caspase-3 can
cleave PARP, and thus inactivate and inhibit PARP's DNA-repairing abilities.
Therefore, cleaved PARP may be considered a marker of late apoptosis [75].
1.2.5. Antioxidant Mechanisms in the Brain
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The brain has a high rate of aerobic metabolism, therefore it is one of the major
organs generating large amounts of ROS and is especially susceptible to oxidative stress.
GSH plays a critical role as an antioxidant in the brain due to its capability to scavenged
multiple ROS [76]. GSH levels can increase or decrease after METH administration,
depending on the severity of METH-induced oxidative stress [77-79]. Thus, changes in
levels of GSH could be a sign of oxidative stress.
1.2.6. METH Neurotoxicity in Experimental Animals vs. Humans
As mentioned above, METH is a neurotoxic drug that causes deficits and alterations
in central DAergic pathways. Repeated administration of METH in rodents has been shown
to cause neurodegeneration of DAergic axon terminals in the striatum. The signs of METHinduced neurodegeneration of DAergic axon terminals include reduced levels of DAergic
markers, for example DAT, VMAT2, and TH as well as the levels of DA and its
metabolites including: 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine (3MT) and homovanillic acid (HVA). These effects occur primarily in the striatum but are
also seen in the cortex, thalamus, hypothalamus, and hippocampus [52, 80]. METH induces
neurotoxicity in a dose-dependent manner [81]. METH has high popularity due to its wide
availability, relatively low cost, and long duration of psychoactive effects. The neurotoxic
effects of METH in humans are similar to those observed in experimental animals. For
example, when administrated at high doses, METH can cause selective decreases in
DAergic and 5-HTergic markers in both experimental animals and humans [82].
Neuroimaging studies of METH abusers have revealed reduction in striatal DAT levels
that are associated with motor slowing and memory impairment [13, 83]. There is also a
report demonstrating that METH alters dentate gyrus (DG) stem cell properties by delaying
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the cell cycle and decreasing self-renewal capacities. DG neurogenesis impairment could
be the mechanism of cognitive deficits verified in METH consumers [84]. These effects
could be manifestations of METH-induced degeneration, however, growing evidence
suggests that neuronal degeneration may not be a part of METH neurotoxicity in human
METH users [85].
1.3. Transposable Elements and Long Interspersed Element 1
1.3.1. METH and Epigenetic Changes
Recently, epigenetics change has attracted much attention as a new and promising
research area in METH abuse [86]. Several studies have reported that acute and chronic
administration of METH can significantly influence the expression of many genes in the
nucleus accumbens and dorsal striatum [87]. Recent reports show that the changes in
histone modifications are related to the expression of genes coding for a variety of proteins
that occur after self-administration of high-dose METH [87]. Moreover, decreased
expression of several histone deacetylases (HDACs) occurs in the striatum after neurotoxic
binge METH [88]. In the substantia nigra, high-dose METH injection over four days can
decrease DNA methylation within the promoter region of alpha-synuclein [89].
1.3.2. Transposable Elements and LINE-1
Activation of transposable elements (TEs) is considered to be an epigenetic change
[90]. Transposable elements are common and naturally occurring sources of genetic
variation known to play diverse roles in genome evolution [91]. However, there are very
few studies that have investigated the effects of METH on TEs in vivo. Among all TEs,
long interspersed element 1 (LINE-1) is the most abundant and active endogenous

13
retroelement, accounting for 17% of the human genome [92, 93]. There are thousands of
copies of LINE-1 in a single human cell, and most of them are silenced under normal
physiological conditions. In the human genome, 80–100 copies of LINE-1 are capable of
retrotransposition [94], and 10% of these are highly active via the copy and paste
mechanism that involves an RNA intermediate and reverse transcriptase activity [95]
(Figure 1.4). A complete cycle of LINE-1 retrotransposition can be associated with DNA
inversions, duplications, or insertions [96]. LINE-1 is 6 kb in length and consists of a
promoter, two open reading frames (ORF-1 and ORF-2), and a poly(A) tail [93, 97]
(Figure1.4). ORF-1 is a basic protein with a nucleic acid chaperone and RNA binding
activity. It is present within cytoplasmic ribonucleoprotein complexes or stress granules in
the cytoplasm [98, 99]. ORF-2 has dual functions of endonuclease [100] and reverse
transcriptase [101]. ORF-1 and ORF-2 mediate LINE-1 retrotransposition, which proceeds
through three steps: transcription, reverse transcription, and insertion of the new
synthesized DNA into the host genome via target site-primed reverse transcription [93,
102]. According to the literature, LINE-1 can be expressed and undergo retrotransposition
at a high frequency in the mammalian nervous system [103, 104]. Furthermore,
deregulation of LINE-1 retrotransposition is involved in some neurological diseases such
as Rett syndrome and ataxia telangiectasia [104]. Since LINE-1 retrotransposition can
change cellular properties by causing gene deletions [105], DNA damage [102], apoptosis
[106], and immune response [107], deregulation of LINE-1 in somatic cells is likely to
occur as either a cause or a consequence of a disease. Our lab has shown that binge METH
increases ORF-2 protein levels in the neurogenic zones of rat brains [86]. In neuronal cell
lines, METH has been shown to trigger retrotransposition of LINE-1 [108].
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Figure 1.3. LINE-1 structure and activation. LINE-1 is 6 kb in length and consists of a
promoter, two open reading frames (ORF-1 and ORF-2) and a poly(A) tail. ORF-1 and
ORF-2 mediate LINE-1 retrotransposition, which proceeds through 3 steps: transcription,
reverse transcription, and insertion of the new synthesized DNA into the host genome via
target site-primed reverse transcription.
1.4. Neurogenic Zones and Neurogenesis
1.4.1. Neurogenesis
The dogma that the adult mammalian brain does not generate new neurons has been
overturned [109]. It has been reported that thousands of new neurons are generated every
day in an adult mammalian brain [110]. Adult neurogenesis is a process of generating
functional neural cell types from neural stem cells and progenitor cells; it is important for
the maintenance of brain integrity and optimal function [111]. This process occurs in two
separate areas of the adult mammalian brain, the subgranular zone (SGZ) and the
subventricular zone (SVZ) [111-113]. In the SGZ of the DG in the hippocampus, adult
neural stem cells undergo proliferation, fate specification, maturation, migration, and
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eventual integration into the pre-existing neural circuitry within the hippocampus [114,
115]. Principal DG cells are the only neuronal subtype that is generated, and newly
generated neurons have distinct properties that enable them to contribute to specialized
functions in learning and memory [116]. Subventricular zone neurogenesis is related to
olfactory bulb formation [117] and may represent a potential source of cells used to repair
damaged brain tissue [118]. In the SVZ of the lateral ventricle, adult neural stem cells give
rise to glia and neuroblasts [117]. These neuroblasts migrate over a long distance to the
olfactory bulb and differentiate into local interneurons that have various functions in
olfaction.
The SGZ is located in the hippocampus between the hilus and the granule cell layer
of the DG (Figure 1.5). Previous studies have shown that after newborn neurons mature
and migrate from the granule layer in the adult DG, they form axonal projections and reach
the CA3 [119]. There are main four types of cells in the SGZ. Type-1 cells (radial-glia-like
stem cells) have astrocyte characteristics and they express GFAP and nestin [120, 121].
Type-1 cells divide asymmetrically. They can either proliferate to other Type-1 cells to
maintain their own population or differentiate into the intermediate cells, called type-2 cells
(neural progenitor cells, 2a and 2b). Type-2 cells generate the migratory neuroblasts known
as type-3 cells. Type-3 cells migrate into the granule cell layer and differentiate into granule
neurons. Type-4 cells, after having ceased mitosis, extend axons toward the CA3, leading
to the development of mature neurons which are positive for neuronal specific nuclear
protein (NeuN) and calbindin. Type-4 cells integrate with the mossy fiber pathway [122].
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Figure 1.4. Neurogenesis in the subgranular zone (SGZ). Top panel: type-1 cells
generate type-2 cells that, in turn, generate type-3 cells; type-3 cells generate immature
neurons that finally become mature neurons. Bottom panel: a sequence of cell types
involved in neuronal lineage and specific markers allowing cell identification are presented.
The SVZ is a second site of neurogenesis in the adult brain. New neurons formed
in this region constantly migrate toward the olfactory bulb to replace interneurons [123].
In the olfactory bulb of adult rats, approximately 80,000 new granular neurons are formed
each day from the SVZ progenitors [124]. The SVZ is formed by three main cell types:
type A, B, and C cells. The type-A cells are migratory neuroblasts. Approximately 33% of
the SVZ cells are type-A cells. They express doublecortin (DCX) and polysialylated
neuronal cell adhesion molecule (PSA-NCAM). They migrate through the rostral
migratory stream (RMS) to the olfactory bulb where they differentiate into granular and
glomerular neurons. In the SVZ, about 23% of cells are type-B cells, which give rise to
type-C cells. Type-B cells are slow proliferating multipotent cells expressing GFAP. They
have the characteristics of astrocytes and can be classified as B1 and B2 cells. B1 cells are
in contact with the lateral ventricle lumen and have a small apical surface, a single basal
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body, and a single short primary cilium. The Type-C cells are transit-amplifying immature
precursor cells that account for about 11% of the SVZ cells. They produce type-A cells and
express the transcription factor distal-less homeobox 2 (Dlx2) [124] and nestin [125].
1.4.2. Markers for Neurogenesis in the Neurogenic Zones
In this study, we used specific markers to differentiate diverse cell types. The
specific markers include: (a) Proliferating cells: Ki-67 is a nuclear protein expressed in
dividing cells for the entire duration of their mitotic activity, the expression of which is
neither linked to DNA repair nor to apoptotic processes. Therefore, it is used as a reliable
marker for proliferating cells) [126, 127]; (b) Immature neurons: DCX can encode a
microtubule-associated protein expressed in migrating neuroblasts therefore it can serve as
a marker of immature neurons [128]; (c) Mature neurons: NeuN, a neuronal specific
nuclear protein, is the most frequently used specific marker for mature neurons [129].
Another common marker for mature neurons is microtubule-associated protein (MAP-2).
(d) Astrocytes: GFAP is a common marker for astrocytes [125].
The cell composition of the SGZ and SVZ and their markers are presented in Figure
1.5 and Figure 1.6, respectively.
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Figure 1.5. Neurogenesis in the subventricular zone (SVZ). Top panel: a sagittal view
of a rodent brain showing the sites of neurogenesis in the SVZ/olfactory (OB) system. Cells
that proliferate in the SVZ migrate along the rostral migratory stream (RMS) to reach the
OB, where they migrate radially and undergo terminal differentiation. Bottom panel: a
sequence of cell types involved in neuronal lineage and specific markers allowing cell
identification are presented. Markers appearing in bold are specific to each stage.
1.4.3. METH effects in the neurogenic zones
METH abuse in humans severely damages the hippocampus, for example by
reducing hippocampal volume and producing hippocampal-dependent memory deficits
[130]. As stated previously, adult neurogenesis has been demonstrated in the hippocampal
SGZ [131]. Recently, it has been shown that a number of external factors, such as drug
abuse can regulate the birth, survival, and fate of newly-generated SGZ progenitors [132].
METH has been reported to dysregulate neurogenesis and induce apoptosis in the
hippocampus and often leads to the death of pyramidal neurons and granular cells [133,
134]. Intermittent (occasional access) and daily (limited and extended access) selfadministration of METH can have an impact on different aspects of hippocampal
neurogenesis [134]. According to a study aiming to clarify the effect of METH on SVZ
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stem/progenitor cell dynamics and neurogenesis, high dosages of METH triggered cell
death both by necrosis and apoptosis, and inhibited the proliferation of progenitor cells in
the SVZ. Furthermore, another study reported that, at non-toxic concentrations, METH
treatment decreased neuronal differentiation and maturation [135].
1.5. Rationale, Objective, and Hypotheses
In our previous study, we found that binge METH increased expression of ORF-2
in the neurogenic zones in rat brains and that some of the ORF-2-positive neurons were
also positive for DCX. But we did not identify all cell types that showed increased ORF-2
levels after METH administration. Additionally, we did not determine the potential
functions of increased ORF-2. The major objective of the current study is to differentiate
the cell populations expressing ORF-2 and to discover whether upregulation of ORF-2 is
associated with oxidative stress and/or apoptosis in the neurogenic zones after exposure to
binge METH.
Our previous study showed that METH can activate LINE-1 in vivo, and trigger
retrotransposition of LINE-1 in vitro [108]. Moreover, TEs undergo retrotransposition
mostly in proliferating cells [135], LINE-1 activation can lead to DNA breakage suggesting
that LINE-1 may cause apoptosis. It has been reported that binge METH induces apoptosis
in the neurogenic zones. Cytoplasmic and extracellular DA levels increase dramatically
after METH exposure [61], which lead to increased ROS production and oxidative stress
[65]. Furthermore, METH-induced increases in GLU release cause mitochondrial
dysfunction thus further potentiating oxidative stress [136]. On the base of these
knowledges, we hypothesized that neurotoxic binge METH would activate LINE-1 in
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proliferating cells in the neurogenic zones and the METH-induced increases in LINE-1
activity would be associated with apoptosis and oxidative stress.

CHAPTER 2: MATERIALS AND METHODS
2.1. Animals
Adult male Sprague-Dawley rats (weighing 250–300g) were accommodated in a
pair-housed, humidity-controlled room and temperature-controlled (20–22 °C). Food and
water were provided. We allowed all the rats to acclimatize for seven days before we start
the research. Our animal procedures have been approved by the Institutional Animal Care
and Use Committee (IACUC) at Wayne State University. All the animal procedures were
conducted between 7:00 A.M. and 7:00 P.M. in strict accordance with the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory. The description of
animal procedures meets the ARRIVE recommended guidelines described by The National
Centre for the Replacement, Refinement, and Reduction of Animals in Research.
2.2 Drug Treatment
(+)-METH hydrochloride (METH, 10 mg/kg free base) (Sigma-Aldrich, St. Louis,
MO) or saline (1 mL/kg) was administered to the rats every 2 h in four successive
intraperitoneal (i.p.) injections. We measured the core body temperatures of the rats before
the starting of saline/ METH administration and the core body temperatures at 1 hour after
each injection and sacrifice the rats 24 hours after the last injection of saline/ METH.
2.3. Tissue Collection and Storage
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We removed the brain from rats and washed with ice-cold phosphate-buffered
saline (PBS). The brains were fixed in 4% paraformaldehyde for 24 h at 4°C. After fixation,
the brains were incubated in 20% and then in 30% glycerol in PBS (24 h in each solution
at 4 °C). Subsequently, the brains were snap-frozen and stored at − 80 °C until assayed.
2.4. Tissue Immunohistochemistry
We checked the protein level via immunofluorescence technique. We used the
tissue sections (40 μm) from the SVZ (1.16 to 0.28 according to Bregma) and the SGZ (−
3.14 to –4.66 according to Bregma). We permeabilized the tissue sections with PBS + 0.1%
triton and did antigen retrieval using 1× citrate buffer for 30-45 min at 90°C. We blocked
the tissue at room temperature using blocking buffer (PBS pH 7.4, 0.1% Triton X-100, and
5% bovine serum albumin (BSA)) for 1 hours after cooled the sections to room temperature.
The sections were then incubated overnight at 4°C with a chicken anti-ORF-2 antibody
(1:200, Rockland Immunochemicals Inc., Limerick, PA) and a cell type marker antibody ,a
rabbit anti-GFAP (1:200, Cell Signaling, Danvers, MA), rabbit anti-NeuN (1:400, Cell
Signaling), rabbit anti-Ki-67 (1:100, Abcam, Cambridge, MA) or rabbit anti-doublecortin
(1:100, Abcam) antibody or an apoptosis marker antibody (a rabbit anti-cleaved PARP
(1:200, Abcam) or rabbit anti-cleaved caspase-3 (1:400, Cell Signaling) antibody. In the
last experiment, the sections were double-labeled with the anti-ORF-2 antibody and mouse
anti-GSH (1:200, Abcam) antibody. The next day, We washed the section with washing
buffer (PBS pH 7.4, 0.1% Triton X-100, and 5% bovine serum albumin (BSA)) for three
times (5 min per washing) and incubated the sections with secondary antibody, antichicken Alexa-488 (1:1000) and anti-rabbit Alexa-594 (1:1000) (Life Technologies,
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Carlsbad, CA) for 2 hours in room temperature. We stained the nuclei using DRAQ5 (Life
Technologies). Lastly, we mounted the sections on slides using Flouromount mounting
medium (Sigma-Aldrich) and cover the slips. We captured the images via Leica TCS SPEII confocal microscope under the 63 × oil objective. These images were then analyzed
using Leica co-localization analysis software. The ORF-2 immunofluorescence was
measured by Image J and averaged. Mean of the averages was then calculated for each rat.
2.5. Cell Culture
PC12 cells (a rat adrenal gland pheochromocytoma cell line) were cultured on
sterilized coverslips (Warner Instrument, Hamden, CT) in the HyClone RPMI-1640
medium (GE Healthcare Life Sciences) containing 5% fetal bovine serum (FBS) and 10%
horse serum. The coverslips were placed in wells of a 24-well plate; each well was seeded
with approximately 50,000 cells.
2.6. Cultured Cells Immunocytochemistry
The next day, the cells were treated with 2mM glutamic acid for 1h, 2h, 3h, 4h, 5h,
6h, 12h or 24h at room temperature. Next, the cells were fixed in 4% paraformaldehyde for
20 min and then permeablized using 0.1% Triton X-100 in PBS for 1h at room temperature.
Subsequently, the cells were blocked in blocking buffer (0.1% Triton X-100, and 1% BSA
in PBS) for 1h at room temperature and incubated overnight at 4°C with the chicken antiORF-2 antibody (1:1000, Rockland Immunochemicals Inc.) or rabbit anti-cleaved caspase3 antibody (1:400, Cell Signaling). The next day, We washed the section with washing
buffer (PBS pH 7.4, 0.1% Triton X-100, and 5% bovine serum albumin (BSA)) for three
times (5 min per washing) and incubated the sections with secondary antibody, anti-
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chicken Alexa-488 (1:1000) and anti-rabbit Alexa-594 (1:1000) (Life Technologies,
Carlsbad, CA) for 2 hours in room temperature. We stained the nuclei using DRAQ5 (Life
Technologies). Lastly, we mounted the sections on slides using Flouromount mounting
medium (Sigma-Aldrich) and cover the slips.
2.7. Statistical Analysis
We analyzed the data using two-way ANOVA (factors: regions and treatment)
followed by Bonferroni post hoc test. Two-way repeated measures (RM) ANOVA was
used for analysis of temperature data. Correlations between measured parameters were
performed using Pearson’s correlation analysis. Significance was set at p < 0.05 (95%
confidence interval) and we further analyzed data using GraphPad Prism program
(GraphPad Software Inc., San Diego, CA, USA).
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Chapter 3 RESULTS
3.1. Binge METH Induces Hyperthermia
In experimental rodents, high doses of METH are known to cause hyperthermia,
which is one of the factors that mediate the neurotoxicity of the drug. An increased core
body temperature can promote the METH induced neuro-toxicity, while a lower body
temperature reduces the METH-induced toxicity [18, 20]. We measured the core body
temperatures of the rats before the starting of saline/ METH administration (baseline
temperatures) and the core body temperatures at 1 hour after each injection. As shown in
Figure 3.1, a significant increase in body temperature was observed in METH-treated
animals (**p<0.005, n=6, by two-way ANOVA followed by Bonferroni post hoc test).
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Figure 3.1. Hyperthermia during binge METH treatment. We observed a significant
increase (F(4,50) = 4.97, **p < 0.005, n=6, by two-way ANOVA) in rat core body
temperature. The two-way ANOVA showed a significant increase in core body
temperature at 1 h (***p < 0.001, n = 6), 3 h (**p < 0.005, n = 6), 5 h and 7 h (*p < 0.05,
n = 6) after binge METH. Abbreviations: h, hour(s); METH, methamphetamine.
3.2. Binge METH Increases ORF-2 Protein Levels in Neurogenic Zones
A previous study conducted in our lab showed that ORF-2 increased in the
neurogenic zones at 24 hours after binge METH [3]. Therefore, we first examined rats’
brains for ORF-2 protein immunoreactivity in the SGZ and SVZ (average of 3 locations
outlined in Fig. 3.2). Similar to previous results, low ORF-2 protein immunoreactivity was
observed in neurogenic zones in the saline-treated rats, while significantly higher ORF-2
protein immunoreactivity was detected in both the SGZ and SVZ in METH-treated rats
(Fig. 3.3) (+75.5%, ***p< 0.001 and +125%, ***p< 0.001, respectively, n=6, by two-way
ANOVA followed by Bonferroni post hoc test), thus confirming the results of our previous
study.

Figure 3.2. A schematic illustration of the subgranular zone (SGZ) and
subventricular zone (SVZ). In the adult rodent brain, (a) the SGZ lies below the granular
cell layer of the DG whereas (b) the SVZ lies between the lateral ventricle and the striatum,
as shown by red markers. Representative images were taken from these 3 regions of the
SGZ (a) and the SVZ (b) per condition (saline vs. METH).
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Figure 3.3. Binge METH increases immunoreactivity of ORF-2 in the neurogenic
zones. Shown are representative images taken from 3 regions of the SGZ (A) and the SVZ
(B). The two-way ANOVA showed significant effect in ORF-2 signal (green) of treatment
(F(1,20) = 13.7, **p < 0.005, n=6) & region (F(1,20) = 128, ***p < 0.001, n=6). Bonferroni
post-tests revealed a significant increase in ORF-2 in both SGZ and SVZ between treatment
(+75.5%, ***p < 0.001, and +125%, ***p < 0.001, n=6). Bonferroni post-tests revealed
significant decrease in ORF-2 in the saline-treated group but not the METH-treated group
between regions (-31.9%, ***p < 0.001, and -9.02%, ***p < 0.001, respectively, n=6). The
data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH,
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone;
SVZ, subventricular zone.
3.3. Identification of Cell Types Expressing Activated LINE-1 in the
Neurogenic Zones after Binge METH
3.3.1. Intermediate progenitor cells and neuronal cells
The intermediate progenitor cells include types 2a, 2b, and 3 cells within the SGZ
and types A and C cells in the SVZ. The cells that proliferate rapidly within the SGZ are
type 2 and some type 3 cells, whereas the cells that proliferate within the SVZ are type A
and C cells. In the SGZ, type 2b and type 3 progenitor cells, as well as postmitotic immature
neurons express DCX protein (Fig.3.6.A). Immature and mature neurons, but not the
intermediate progenitor cells, can be identified by NeuN protein in this zone (Fig.3.7.A).
In the SVZ, neuroblasts express DCX (Fig.3.6.B) while mature neurons express NeuN
(Fig.3.7.B). MAP2, as a marker of neuronal cells, can be used for cytoskeleton staining.
LINE-1 is activated and readily retrotransposes in proliferating cells. Therefore, we
first tested whether binge METH would activate LINE-1 in cells proliferating within the
neurogenic zones. We found that, compared to the saline group, binge METH treatment
can slightly increase immunoreactivity of Ki-67, a marker of proliferating cells, in the SGZ
and SVZ (+9.22%, p > 0.05 and +21.5%, *p < 0.05, respectively, n=6, by two-way
ANOVA followed by Bonferroni post hoc test) at 24 hours after the last injection of the
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drug (Fig. 3.4.A-C). We also found that some ORF-2 immunoreactivity co-localized with
Ki-67 immunoreactivity (in the same compartment or cell type) in both saline and METHtreated rats (Fig. 3.4.A-B). Statistically, METH treatment did not significantly change colocalization of the ORF-2 signal with the Ki-67 signal in the SGZ and SVZ when assessed
by Pearson’s correlation analysis (+42.2%, p > 0.05; +17.9%, p > 0.05, respectively, n=6,
by two-way ANOVA followed by Bonferroni post hoc test) (Fig. 3.4.C.b). This finding
was not surprising as Ki-67 localizes mainly in the nucleus while ORF-2 localizes primarily
in the cytoplasm. Therefore, we next counted the cells that expressed both proteins
regardless of the sub-cellular compartment. As compared to the saline controls, the METHtreated rats expressed, on average, 19.2 cells (vs. 12.3 cells in saline group) that expressed
both proteins in the SGZ, which was a 56.1% increase. In the SVZ, 7.63 cells (vs. 5.78
cells in saline group), on average, expressed both proteins in METH-treated rats, which
translated to a 32.0% increase compared to the saline control (Fig. 3.5).
We used DCX as a marker of precursor (type-2b and type-3 cells) and immature
neuronal cells to discover if neurotoxic binge METH could activate LINE-1 in any of these
types of cells. As shown in our previous study [86], many but not all ORF-2-positive
neurons were also positive for DCX in both the saline- and METH-treated rats (Fig.3.5).
However, statistically, binge METH did not show a significant effect on the
immunoreactivity of DCX in the SGZ and SVZ (+10.3%, p > 0.05, and +20.0%, p > 0.05,
respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test) (Fig.3.6.AC). Similarly, binge METH did not affect the co-localization of the ORF-2 signal with
DCX signal in the SGZ and SVZ (F(1,12) = 4.52, p > 0.05, n = 4, by two-way ANOVA)
(Fig.3.6.C.b). In addition to proliferating precursor cells and immature neurons, there are
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mature neuronal and glial cells within the neurogenic zones. Immunostaining for NeuN, a
classic marker of postmitotic neurons, revealed binge METH significantly decreased the
immunoreactivity of NeuN in the SGZ and SVZ (-15.31%, ***p<0.001 and -38.15%,
*p<0.05, respectively, n=6, by two-way ANOVA followed by Bonferroni post hoc test)
(Fig. 3.7.C.a). At the same time, binge METH increased co-localization of the ORF-2
signal with the NeuN signal in the SGZ but not the SVZ compared to the saline group
(+74.58%, **p<0.005, and +7.66%, p > 0.05, respectively, n=6, by two-way ANOVA
followed by Bonferroni post hoc test) (Fig.3.7.b).
The ORF-2 signal did not co-localize with the MAP2 (marker of neuronal cells)
signal in the cytoskeleton outside the neurogenic zones (Fig.3.8).
The result suggests that systemic administration of neurotoxic doses of binge
METH increased the activity of LINE-1 in postmitotic neurons in the SGZ.
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Figure 3.4. Binge METH does not change immunoreactivity of Ki-67 in the
neurogenic zones. Representative images from 3 regions of the SGZ (A) and the SVZ (B)
per condition (SAL and METH) were taken. The Ki-67 protein signals (pink) showed
increase in METH-treated rats compared to the saline-treated rats The two-way ANOVA
showed significant effect in Ki-67 signal of treatment (F(1,20) = 6.40, *p < 0.05, n=6) and
region (F(1,20) = 7.37, *p < 0.05, n=6). Bonferroni post-tests did not reveal significant
difference in Ki-67 in SGZ but showed a significant increase in SVZ between treatment
(+9.22%, p > 0.05, and +21.5%, *p < 0.05, respectively, n=6). Bonferroni post-tests
revealed a significant increase in Ki-67 in the saline-treated group but not the METHtreated group between SGZ and SVZ (+10.4%, *p < 0.05, and +22.8%, p > 0.05,
respectively, n=6). Some ORF-2-positive neurons (green) are positive for Ki-67 (arrows),
which is a selective marker of proliferating cells, in both saline- and METH-treated rats.
METH does not change co-localization of ORF-2 signal with Ki-67 signal in neurogenic
zones. The two-way ANOVA did not show significant effect in co-localization of ORF-2
and Ki-67 of treatment (F(1,20) = 2.47, p > 0.05, n=6) & region (F(1,20) = 3.72, p > 0.05,
n=6). The data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH,
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone;
SVZ, subventricular zone.
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Figure 3.5. Number of cells expressing both ORF-2 immunoreactivity and Ki-67
immunoreactivity. The two-way ANOVA showed significant effect in number of cells
that express both ORF-2 and Ki-67 of treatment (F(1,20) = 49.2, ***p<0.001, n=6) and
region (F(1,20) = 11.6, **p < 0.05, n=6). Bonferroni posttests revealed a significant
increase in SGZ but not SVZ between treatment (+56.1%, **p < 0.005, and +32.0%, p >
0.05, n=6). Bonferroni posttests revealed a significant increase in the saline-treated group
and the METH-treated group between regions (-53.0%, **p < 0.005, and -60.3%, ***p <
0.001, respectively, n=6). Nuclei are depicted in blue. Abbreviations: METH,
methamphetamine; SAL, saline; ORF-2; open reading frame 2; SGZ, subgranular zone;
SVZ, subventricular zone.
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Figure 3.6. Binge METH has no effect on the immunoreactivity of DCX in the
neurogenic zones. Representative images from 3 regions of the SGZ (A) and the SVZ (B)
per condition (saline and METH) were taken. The two-way ANOVA showed a significant
effect in DCX signal (red) of treatment (F(1,12) = 11.3, *p < 0.05, n=4), but did not show
significant effect in DCX signal of region (F(1,12) = 1.01, p > 0.05, n=4). Bonferroni
posttests didn`t reveal significant difference in DCX signal in neither SGZ nor SVZ
between treatment (+10.3%, p > 0.05, and +20.0%, p > 0.05, respectively, n=4)Some ORF2-positive neurons (green) are also positive for DCX (arrows), which is a selective marker
of immature and type-3 cells, in both the saline- and METH-treated rats. METH does not
change co-localization of ORF-2 signal with DCX signal in the neurogenic zones The twoway ANOVA did not show significant effect in co-localization of ORF-2 and DCX of
treatment (F(1,12) = 4.52, p > 0.05, n=4), but it showed a significant increase in region
(F(1,12) = 7.08, *p < 0.05, n=4). Bonferroni posttests didn`t reveal significant difference
in DCX signal (red) in neither SGZ nor SVZ between treatment (+10.3%, p > 0.05, and
+20.0%, p > 0.05, respectively, n=4). . The data are summarized in (C). Nuclei are depicted
in blue. Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open reading
frame 2; SGZ, subgranular zone; SVZ, subventricular zone.

35

36
Figure 3.7. Binge METH decreases the immunoreactivity of NeuN in the SGZ.
Representative images from 3 regions of the SGZ (A) and the SVZ (B) per condition (saline
and METH) were taken. The two-way ANOVA showed significant effect in NeuN signal
(pink) of treatment (F(1,20) = 1378, ***p < 0.001, n=6) and region (F(1,20) = 40.0, *p <
0.05, n=6). Bonferroni posttests revealed a significant decrease in NeuN signal (pink) in
SGZ and SVZ between treatment (-15.31%, ***p < 0.001 and -38.15%, *p < 0.05,
respectively, n=6). Bonferroni posttests revealed a significant decrease in NeuN signal in
the saline-treated group and the METH-treated group between SGZ and SVZ (-83.2%,
***p < 0.001 and -76.7%, ***p < 0.001, respectively, n=6).Some of ORF-2-positive
neurons (green) are also positive for NeuN (arrows), a selective marker of mature neurons,
in both the saline- and METH-treated rats. The two-way ANOVA showed a significant
increase in co-localization of ORF-2 and NeuN of treatment (F(1,20) = 77.1, ***p < 0.001,
n=6), and region (F(1,20) = 15.00, ***p < 0.001, n=6). Bonferroni posttests revealed
significant increase in co-localization between ORF-2 and NeuN in SGZ but not SVZ after
binge METH (+74.58%, **p < 0.005, and +7.66%, p > 0.05, respectively, n=6). Bonferroni
posttests revealed significant increase in co-localization in the saline-treated group and the
METH-treated group between regions (+152%, ***p < 0.001 and +72.0%, ***p < 0.001,
respectively, n=6). The data are summarized in (C). Nuclei are depicted in blue.
Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open reading frame; SGZ,
subgranular zone; SVZ, subventricular zone.

Figure 3.8. The ORF-2 signal does not co-localize with the MAP2 signal in
cytoskeleton outside the neurogenic zones. METH (10 mg/kg free base) was
administered to young adult male Sprague-Dawley rats every 2h in four successive
intraperitoneal (i.p.) injections and the rats were killed 24h later. The ORF-2 signal (green)
does not co-localize with the MAP2 signal (red) outside the SGZ (A) or SVZ (B) after
METH treatment.
3.3.2. Radial glial-like stem cells and mature glial cells
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Radial glia-like stem cells and mature glia both express GFAP protein; however,
they differ in localization and shape. In the SGZ, radial glia-like cells reside at the bottom
of the zone (adjacent to the hilus) and have small cell bodies with short processes, while
mature glia reside mostly at the top and outside of the zone and are star-shaped with long
processes (Fig.3.10). In the SVZ, radial glia-like cells are mostly located adjacent to the
ventricle, while the majority of mature glia localize close to the striatum.
We have detected that binge METH increased the immunoreactivity of GFAP in
the SGZ and SVZ and their immediate proximity (+44.6%, **p < 0.005 and +120%, ***p
< 0.001, respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test).
We also observed that most of the ORF-2 immunoreactivity co-localizes with GFAP
immunoreactivity in both zones and METH treatment significantly increased the colocalization of both SGZ and SVZ (+85.3%, ***p < 0.001 and +130%, ***p < 0.001,
respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test.) (Fig.3.9).
The ORF-2 signal co-localized with the GFAP signal in both radial and mature glia in the
DG (Fig.3.10).
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Figure 3.9. Binge METH increases immunoreactivity of GFAP in the neurogenic
zones. Representative images from 3 regions of the SGZ (A) and the SVZ (B) per
condition (saline and METH) were taken. The two-way ANOVA showed a significant
increase in GFAP signal (red) of treatment (F(1,12) = 1.99, ***p < 0.001, n=4) but not
region (F(1,12) = 63.7, p > 0.05, n=4). Bonferroni posttests revealed a significant increase
in GFAP signal in SGZ and SVZ between treatment (+44.6%, **p < 0.005 and +120%,
***p < 0.001, respectively, n=4). ORF-2-positive neurons (green) are also positive for
GFAP (arrows), which is a selective marker of radio-glial-like and mature glial cells, in
both the saline- and METH-treated rats. The two-way ANOVA showed a significant
increase in co-localization of ORF-2 and GFAP of treatment (F(1,12) = 27.9, ***p < 0.001,
n=4), and region (F(1,12) = 201, ***p < 0.001, n=4). Bonferroni posttests revealed a
significant increase in co-localization between ORF-2 and GFAP in SGZ and SVZ after
binge METH (+85.3%, ***p < 0.001, and +130%, ***p < 0.001, respectively, n=4).
Bonferroni posttests did not reveal significant difference in co-localization in the salinetreated group between regions. But it showed a significant increase in the METH-treated
group between SGZ and SVZ (+12.6%, p > 0.05 and +40.0%, ***p < 0.001, respectively,
n=4). The data are summarized in (C). Nuclei are depicted in blue. Abbreviations: METH,
methamphetamine; SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ,
subventricular zone.
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Figure 3.10. The ORF-2 signal co-localizes with the GFAP signal in different types of
glial cells of the SGZ after METH exposure. METH (10 mg/kg free base) was
administered to young adult male Sprague-Dawley rats every 2h in four successive
intraperitoneal (i.p.) injections and the rats were killed 24h later. ORF-2 signal (green)
signal co-localize with GFAP signal (red) in both mature glial cells (A) and radio-glial cells
(B).

3.4. The Role of LINE-1 in the Neurogenic Zones
So far, we have demonstrated that systemic administration of neurotoxic doses of
binge METH increases the activity of LINE-1 in glial cells and postmitotic cells in the
neurogenic zones. We further investigated the role of increased ORF-2 in these types of
cells. As mentioned before, administration of high doses of METH can cause oxidative
stress, inflammatory response, and neuronal apoptosis, which lead to damage of DAergic
and 5HTergic neuronal terminals (neurotoxicity). [137]. We would like to determine
whether binge METH-induced increase of LINE-1-encoded ORF-2 protein is associated
with apoptosis and/or oxidative stress. Therefore, we next stained the tissue using the
markers specific for different stages of apoptosis and oxidative stress. We found that binge
METH significantly increased immunoreactivity of cleaved caspase-3, which localized
mostly in the nucleus, in the SGZ and SVZ (+71.4%, ***p < 0.001 and +92.3%, ***p <
0.001, respectively, n=4, by two-way ANOVA followed by Bonferroni post hoc test). This
result was consistent with the existing knowledge that exposure to a high dose of METH
induces apoptosis. Moreover, METH treatment can significantly increase the colocalization of ORF-2 immunoreactivity and cleaved caspase-3 immunoreactivity in the
SGZ and SVZ (+25.2%, p > 0.05 and +68.42%, ***p < 0.001, respectively, n=4, by twoway ANOVA followed by Bonferroni post hoc test) compared to saline controls (Fig.3.11).
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Commonly, cleaved caspse-3 localize in the cytoplasm. To verify the reliability of the
cleaved caspase-3 antibody, we treated PC12 cells with glutamic, an acid-stress factor, and
stained the cells with cleaved caspase-3 antibody. The cleaved caspase-3 was observed in
the cytoplasm (Fig.3.12). Subsequently, we used cleaved PARP as a marker of late stage
apoptosis and found that METH did not significantly increase the signal of cleaved PARP
in the SGZ and SVZ (+22.3%, p > 0.05 and +18.7%, p > 0.05 respectively, n=6, two-way
ANOVA followed by Bonferroni post hoc test). Furthermore, METH treatment did not
change the co-localization of the ORF-2 signal and cleaved PARP signal in the SGZ and
SVZ (F(1,20) = 0.113, p > 0.05, n = 6, by two-way ANOVA) (Figure 3.13). We also
performed a triple staining study and found that the ORF-2 signal co-localizes with the
cleaved-PARP signal in few immature (Figure 3.14) and proliferating (Figure 3.15) neuron
cells within the neurogenic zones. All these results show that the ORF-2 signal co-localizes
with some, but not all, apoptotic markers within the neurogenic zones after METH
treatment, suggesting that METH-induced increases in ORF-2 may not be associated with
apoptosis.
An increased level of GSH often indicates an adaptive response to oxidative stress.
Interestingly, we found that binge METH significantly increased immunoreactivity of GSH
in the SGZ and SVZ (+28.4%, *p < 0.05 and +46.9%, p > 0.05n = 6, by two-way ANOVA
followed by Bonferroni post hoc test). METH also significantly increased co-localization
of ORF-2 with GSH in the SGZ and SVZ (+24.6%, ***p < 0.001and +57.7%, ***p < 0.001,
respectively, n = 6, by two-way ANOVA followed by Bonferroni post hoc test) (Figure
3.16). Our data also showed that the ORF-2 signal co-localized with the GSH signal in
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most cells within the neurogenic zones. We can conclude that binge METH-induced
increase of ORF-2 may be associated with responses to oxidative stress.
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Figure 3.8. Binge METH increases immunoreactivity of cleaved caspase-3 and ORF2 immunoreactivity co-localizes with cleaved caspase-3 immunoreactivity in the
neurogenic zones. Representative images from 3 regions of the SGZ (A) and the SVZ (B)
(saline and METH) were taken. The two-way ANOVA showed a significant increase in
cleaved caspase-3 signal (pink) of treatment (F(1,12) = 87.8, ***p < 0.001, n=4) but not
region (F(1,12) = 4.18, p > 0.05, n=4). Bonferroni posttests revealed a significant increase
in cleaved caspase-3 signal in SGZ and SVZ between treatment (+71.4%, ***p < 0.001
and +92.3%, ***p < 0.001, respectively, n=4).ORF-2-positive neurons (green) are also
positive for cleaved caspase-3 (arrows), a selective marker of middle stage of apoptosis, in
both the saline- and METH-treated rats. The two-way ANOVA showed a significant
increase in co-localization of ORF-2 and cleaved caspase-3 of treatment (F(1,12) = 12.4,
**p < 0.005, n=4), and region (F(1,12) = 24.8, ***p < 0.001, n=4). Bonferroni posttests
did not reveal significant increase in co-localization between ORF-2 and cleaved caspase3 in SGZ but showed a significant increase in SVZ after binge METH (+25.2%, p > 0.05,
and +68.4%, ***p < 0.001, respectively, n=4). Bonferroni posttests did not reveal
significant difference co-localization of ORF-2 and cleaved caspase-3 in co-localization in
saline between regions. But it showed a significant increase in METH between SGZ and
SVZ (+18.7%, p > 0.05 and +50.3%, **p < 0.005, respectively, n=4).The data are
summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, methamphetamine;
SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ, subventricular
zone.
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Figure 3.9. Cleaved caspase-3 immunoreactivity in PC12 cells. Cells were treated with
2mM glutamic acid for 4h (right) & untreated cells (left). After glutamic acid treatment,
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Figure 3.10. Binge METH increases immunoreactivity of cleaved PARP. ORF-2 signal
co-localizes with cleaved PARP signal in the SVZ. Representative images from 3 regions
of the SGZ (A) and the SVZ (B) (as shown in Figure3.2) per condition (saline (a) and
METH (b)) were taken. The two-way ANOVA showed a significant increase in cleaved
PARP signal (red) of treatment (F(1,20) = 28.8, ***p < 0.001, n=6) and region (F(1,20) =
8.62, **p < 0.005, n=6). However, bonferroni posttests did not show significant difference
in cleaved PARP signal in SGZ and SVZ between treatment (+22.3%, p > 0.05 and +18.7%,
p > 0.05, respectively, n=6). Bonferroni posttests revealed a significant increase in cleaved
PARP signal in the saline-treated group and the METH-treated one between regions
(+48.8%, **p < 0.005 and +45.6%, ***p < 0.001, respectively, n=6). ORF-2-positive
neurons (green) were also positive for cleaved PARP(arrows) , which is a selective marker
of the late stage of apoptotic cells, The two-way ANOVA did not show significant
difference in co-localization of ORF-2 and cleaved PARP of treatment (F(1,20) = 0.113,
p > 0.05, n=6). But it showed a significant increase in region (F(1,20) = 6.04, *p < 0.05,
n=6). Bonferroni posttests did not reveal significant increase in co-localization between
ORF-2 and cleaved PARP in neither the saline-treated group nor the METH-treated group
between regions (+87.6%, p > 0.05, and +78.3%, p > 0.05, respectively, n=6). The data are
summarized in (C). Nuclei are depicted in blue. Abbreviations: METH, methamphetamine;
SAL, saline; ORF-2; open reading frame; SGZ, subgranular zone; SVZ, subventricular
zone.

Figure 3.11. ORF-2 signal co-localizes with the cleaved-PARP signal in some
immature neuron cells within the neurogenic zones. Single plain shows that ORF-2
signal (green) co-localizes with the cleaved-PARP signal (red) in some DCX (white)
positive cells within the neurogenic zones after binge METH.
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Figure 3.12. ORF-2 signal co-localizes with the cleaved-PARP signal in some
proliferating neuronal cells within the neurogenic zones. Single plain shows that ORF2 signal (green) co-localizes with the cleaved-PARP signal (red) in some Ki-67(white)
positive cells within the neurogenic zones after binge METH.
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Figure 3.13. Binge METH increases immunoreactivity of GSH. ORF-2 signal colocalizes with GSH signal in both SGZ and SVZ. Representative images from 3 regions
of the SGZ (A) and the SVZ (B) (as shown in Figure3.2) per condition (saline (a) and
METH (b)) were taken. The two-way ANOVA showed a significant increase in GSH signal
(red) of treatment (F(1,20) = 75.6, ***p < 0.001, n=6) and region (F(1,20) = 10.7, **p <
0.005, n=6). Bonferroni posttests showed a significant increase in GSH signal in SGZ but
not SVZ between treatment (+28.4%, *p < 0.05 and +46.9%, p > 0.05, respectively, n=6).
Bonferroni posttests revealed a significant decrease in GSH signal in the saline-treated
group and the METH-treated group between SGZ and SVZ (-58.9%, ***p < 0.001 and 52.9%, ***p < 0.001, respectively, n=6). Some ORF-2-positive neurons (green) were also
positive for GSH (arrows) (red), which is a selective marker of oxidative stress, in both
saline- and METH-treated rats. The two-way ANOVA showed a significant increase in colocalization of ORF-2 and GSH of treatment (F(1,20) = 584, ***p < 0.001, n=6), and region
(F(1,20) = 124, ***p < 0.001, n=6). Bonferroni posttests revealed a significant increase in
co-localization between ORF-2 and GSH in both SGZ and SVZ between treatment
(+24.6%, ***p < 0.001, and +57.7%, ***p < 0.001,, respectively, n=6). Bonferroni
posttests revealed a significant decrease in co-localization between ORF-2 and GSH in
both the saline-treated group and the METH-treated group between SGZ and SVZ (-55.4%,
p > 0.05, and -43.8%, p > 0.05, respectively, n=6). The data are summarized in (C). Nuclei
are depicted in blue. Abbreviations: METH, methamphetamine; SAL, saline; ORF-2; open
reading frame; SGZ, subgranular zone; SVZ, subventricular zone.
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Chapter 4 DISCUSSION
4.1. Binge METH Increases ORF-2 Protein Levels in the Neurogenic Zones
As demonstrated earlier, LINE-1 is a repetitive DNA retrotransposon, which can
be activated and inserted into a genome by a copy-and-paste genetic mechanism [95]. It
encodes two proteins; one protein is ORF-1, an RNA-binding protein, and the other is
ORF-2, an endonuclease and reverse transcriptase. Both proteins are required for LINE-1
retrotransposition, and increase of the proteins can serve as a sign of LINE-1 activation. In
this study, we used the increased level of ORF-2 protein as the sign of LINE-1 activation.
We observed that binge METH can increase the ORF-2 protein level in the neurogenic
zones, suggesting the LINE-1 activation. These results confirm our previous findings. Our
group has reported previously that increased levels of ORF-2 were observed in the SGZ
and SVZ at 24 hours after the last dose of binge METH [86], suggesting that METHtriggered LINE-1 activation in the cells residing in the neurogenic zones. Earlier studies
indicated that LINE-1 is active in very early embryogenesis, and the insertion of LINE-1
has been detected in neoplastic cells [138, 139]. In normal adult somatic cells, with
exception of germ cells, LINE-1 is typically quiescent within the genomes of mammals
[140]. Moreover, there is both evidence for transposition of LINE-1 in neurons [141] and
evidence for LINE-1 activation in the SGZ [134]. Most importantly, cellular stresses such
as thermal, oxidative, and genotoxic stress can induce LINE-1 activation [142, 143]
because neurotoxic doses of binge METH cause hyperthermia as well as oxidative damage
to proteins, lipids, and DNA [9, 144].
4.2. Identification of Cell Types Expressing Activated LINE-1 in the
Neurogenic Zones after Binge METH
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4.2.1. Intermediate progenitor cells and neuronal cells
In our previous study [86], after binge METH, ORF-2 increased in both DCXpositive and DCX-negative cells in the SGZ and SVZ. Doublecortin is a microtubuleassociated protein expressed in type-2b, type-3, and immature granule cells. Therefore,
previous results indicated LINE-1 activation in neuronal precursors was not only
differentiating and maturing into neurons but also in other cell types.
To identify additional cells types in which ORF-2 expression is increased after
binge METH in the neurogenic zones, we used two neuronal markers (NeuN, MAP2) and
a marker of proliferating cells (Ki-67) in this study. Firstly, to confirm the previous results,
we stained the tissue with ORF-2 and DCX. We found that the level of DCX remained the
same at 24 hours after binge METH. It has been reported that METH (10 nM) can increase
DCX protein levels, suggesting a potentially enhanced neuronal differentiation. In the same
study, the results also demonstrated that METH altered DG stem cell properties by delaying
the cell cycle and decreasing self-renewal capacities [84]. However, another study showed
that METH had a negative impact on SVZ stem/progenitor cells, inducing cell death and
inhibiting neurogenesis. Specifically, METH decreased neuronal differentiation and
maturation at non-toxic concentrations (1-10nM) [135]. In our study, the non-changed level
of DCX could be explained by the supposition that the suppression of cell proliferation or
differentiation occurred earlier or later than 24 hours after binge METH. Alternatively, it
is also possible that initially METH did increase cell differentiation in the SGZ and SVZ
but later caused the death of differentiating cells which masked the increase. This
possibility is supported by the results of triple staining for DCX, cleaved PARP, and ORF2. Only some DCX and cleaved PARP double-positive cells express ORF-2, suggesting
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that METH treatment may promote death of DCX-positive cells in the neurogenic zones.
To explain this discrepancy, an in vitro study in PC12 cells may be necessary to further
determine the timeline of METH effects in cell proliferation. Our results are in agreement
with the results of the Muotri group [141]. They found that engineered LINE-1
retrotransposed in differentiated neuronal precursors derived from rat hippocampus neural
stem cells. Regarding the effect of binge METH on DCX levels, our finding- that there was
no difference between the saline and METH rats, agrees with Mandyam’s group’s results,
who found that intermittent access to METH self-administration had no effect on the
number of DCX-positive cells in the SGZ [134]. Collectively, these data suggest that
METH has a different effect on DCX-positive cells in the SGZ, depending on the dose,
frequency of administration, and stage of cell differentiation.
Recent studies have disclosed that METH induces a reduction of proliferation in
both the SVZ and the SGZ [145, 146]. In our study, however, a slight increase of Ki-67
was observed in the SVZ at 24 hours after binge METH administration. It has been reported
that acute injection of METH produced a rapid and transient (lasting 7 days) decrease in
the number of BrdU-positive cells in the rat striatum, but it had no effect on cells in the
SVZ or DG [147]. Similarly, it was found that acute treatment with METH (25 mg/kg; i.p.)
suppressed the proliferation of granule cells in the DG of adult gerbils, and this effect was
transient (the proliferation rate was restored 36 hours after the drug challenge) [148]. Dr.
Mandyam’s group studied proliferation of progenitors using Ki-67 labeling in rats
intravenously self-administering METH for an extended access (6 h/day: long access
(LgA)) or limited access (1 h/day: short access (ShA)). They found that four sessions of
LgA METH enhanced proliferation while 42 sessions of ShA and LgA METH reduced
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proliferation [149]. Their group also found that when adult rats were given intermittent
(occasional) access to METH for 1 hour twice a week, an initial pro-proliferative effect
was produced, but opposing effects on late progenitors and postmitotic neurons resulted in
no overall change in neurogenesis [150]. These findings demonstrate the dynamic
regulation of neurogenesis by METH, and underscore how diverse durations of METH
access alter distinct aspects of neurogenesis.
We did not find a significant difference of co-localization of ORF-2 and Ki-67
between saline and METH treatment using Pearson`s correlation coefficient. However, via
manually counting the ORF-2 and Ki-67 double positive cells, a significant increase of the
double positive cells in the neurogenic zone was observed in the METH treated group.
Banaz`s group transfected porcine aortic endothelial (PAE) with a LINE-1 expression
vector and generated cell clones harboring retrotransposition events. They demonstrated
that LINE-1 retrotransposition events lead to the reduction of endothelial cell proliferation
and migration in a PAE cell mode [151]. Fan’s group structured a siRNA expression vector
for the LINE-1 ORF-1 encoding sequence and transfected hepatocellular carcinoma cells
(Bel-7402, SMMC-7721, HepG2) and immortalized hepatocellular cells (LO2). They
found that the transfection of a LINE-1 ORF-1p siRNA expression vector can efficiently
reduce the expression of LINE-1 ORF-1 protein detecting by Western blot, and the
decrease of LINE-1 ORF-1 protein inhibited the proliferation of the above cells on the third
day (FENG Fan; Regulatory effect of LINE-1 ORF-1p on hepatocellular carcinoma cells
and proliferation of immortalized hepatocellular cells; Medical Journal of Chinese People's
Liberation Army 2012-03). However, Li’s group found that overexpression of LINE-1
ORF-1 protein promoted human colorectal cancer LoVo cell proliferation, and the
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proliferation of LoVo cells can be inhibited by knocking down the LINE-1 protein using
siRNA against LINE-1. The in vivo data revealed that LINE-1 ORF-1 protein
overexpression promoted LoVo tumor growth in nude mice, whereas the siRNA
knockdown of endogenous LINE-1 ORF-1 protein inhibited tumor growth. These results
indicated that LINE-1 ORF-1protein could promote LoVo cell proliferation and invasion
both in vitro and in vivo [152]. Those evident revealed that proliferation accompanies
LINE-1 activation, which supported our results. However, both double staining and triple
staining showed that only some ORF-2 positive cells are indeed proliferating cells.
Regarding mature neurons, we found that binge METH decreases the expression of
NeuN in the neurogenic zones. Moreover, we did not find a decrease in DCX-positive
neurons. Therefore, it is possible that some of the mature neurons died as a result of binge
METH neurotoxicity. Previous studies have shown that METH can not only dysregulate
neurogenesis but also induce apoptosis, which was followed by death of pyramidal and
granule neurons [133, 134]. There are studies that have demonstrated that METH treatment
can induce cell death of calbindin-containing GABA interneurons within the hippocampus
in animal models [45, 47]. Our result further supports the conclusion that binge METH
induces apoptosis in the neurogenic zones. Since ORF-2 was not enriched in DCX-positive
cells, the results suggest that ORF-2 was activated in mature granule neurons by binge
METH, and that the mature neurons were more susceptible to the effects of neurotoxic
METH doses than differentiating and immature neurons.
There is some evidence indicating that LINE-1 is activated in mature cells under
certain circumstances. For example, LINE-1 retrotransposition has been found in mature
endothelial cells in addition to endothelial progenitors [151]. Higher LINE-1 DNA
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methylation levels in the cumulus cells of mature oocytesin Polycystic Ovary Syndrome
(PCOS) patients than control patients, have been observed. But there was no difference in
the methylation of cumulus cells in immature oocytes between PCOS and control patients.
Muotri’s group first discovered that LINE-1 is capable of retrotransposition in these cells
that also expressed the neuronal marker NeuN [141]. Garcia-Perez’s group further
demonstrated for the first time that engineered LINE-1 can retrotranspose efficiently in
mature nondividing neuronal cells. Thus, these findings have proved that the degree of
somatic mosaicism and the impact of LINE-1 retrotransposition in the human brain may
be higher than previously thought [153]. However, there is no study testing LINE-1 level
in mature cells after METH administration. Here, we found that increased amounts of ORF2 and NeuN double positive cells were observed in neurogenic zones after METH treatment.
The possible reasons why we did not see much co-localization between ORF-2 and NeuN
in SVZ follow. Firstly, there are fewer mature neuron cells in the SVZ compared with the
SGZ, based on our staining. There are primarily three cell types in the SVZ: type-A, typeB, and type-C cells. Type-B cells have characteristics of astrocytes and have the potential
to generate type-C cells, which are the transit-amplifying progenitor cells. The type-C cells
can further produce type-A cells, which are migrating neuroblasts. Therefore, there is a
limited number of mature neuron cells in the SVZ. The SVZ has new GABA- and DAcontaining interneurons and these neurons can migrate to the olfactory bulb in most adult
mammals[154]. METH has been reported to induce apoptosis in these interneurons [155157]. According to our data, most NeuN positive cells are located in the portion of the
striatum adjacent to the SVZ but not within the SVZ. Secondly, there are many types of
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mature neuronal cells in the brain. It is possible that LINE-1 only retrotransposes in certain
types of mature neuron cells.
Microtubule-associated protein2 is one of the most frequently used markers for
mature neurons [158, 159], which can stain the whole cell body. Therefore, we used MAP2
to determine whether LINE-1 affects the cytoskeleton. However, we did not detect the colocalization between ORF-2 and MAP2 signals in the cytoskeleton, which indicated that
METH-related increases in ORF-2 may not be expressed in the cytoskeleton.
4.2.2. Radial glial-like stem cells and mature glial
METH has been reported to trigger inflammatory responses in areas where DA and 5-HT
terminals are damaged. METH affects glial cell (e.g., microglia and astrocytes) activity.
On the other hand, glial cell activity can modulate the neurotoxic and addictive effects of
METH [55, 56]. Goncavalez and colleagues found that massive METH doses (30 mg/kg)
increased GFAP levels in the hippocampi of mice [160]. We found a similar result, that
binge METH increased expression of GFAP in the neurogenic zones and neighboring CA13 regions, which was likely due to METH’s neurotoxic effects. So far there is no data on
testing LINE-1 levels in glial cells after METH administration. Our observation that many
GFAP-positive cells were also positive for ORF-2 suggested that ORF-2 may be mediating
the inflammatory response in the hippocampi of binge METH-exposed rats.

The

Muotri group’s results indicated that the glial cells did not support high levels of
retrotransposition because there was no LINE-1 detected in S100-β-positive [141].
However, they discussed that they could not conclude that LINE-10eGFP transgene was
silencing in glia based on their limited results. Another in vitro experiment based on an
engineered LINE-1 reporter indicated that glia may support less LINE-1 mobilization than
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neurons. They transfected human fetal brain stem cells (hCNS-SCns) with an expression
construct containing a retrotransposition-competent human LINE-1 driven from its native
promoter, which consisted of a reversed copy of the enhanced green fluorescent protein
(EGFP) expression cassette. They found EGFP-positive cells can preferentially
differentiate into glial cells rather than neurons [103]. There is another observation in
human postmortem tissues that suggests LINE-1 retrotransposition events occur more often
in neurons than in glia [161, 162]. Upton’s group performed single-cell retrotransposon
capture sequencing (RC-seq) on individual human hippocampal neurons and glial cells.
They obtained a mean true positive estimate of 6.5 insertions per glial cell, based on the
PCR validation rate determined for hippocampal neurons (45.0%). This rate was 52.6%
lower than the estimated 13.7 insertions for hippocampal neurons. This result means that
LINE-1 insertions can arise in proliferating neural stem cells prior to glial or neuronal
commitment, while glial otherwise support less LINE-1 mobilization than neurons.
However, our result showed that ORF-2 level increased significantly in GFAP-positive
cells after METH administration, both in mature astrocytes outside the SGZ and SVZ, and
in gasket cell within the SGZ and SVZ. To explain this, first of all, we must admit that the
result of an in vitro study may be different than an in vivo study. Secondly, GFAP is a
specific marker for mature astrocytes, but it is also a marker of the radial-glia-like type-1
cells which may limit its use in differentiating the cellular population [163]. It is necessary
to distinguish radial glia-like cells and mature glial cells. These two types of cells are
different in structure: radial glia-like cells are more like tadpoles, while glial cells have a
star-like morphology. As mentioned before, they also have different locations. From our
data, ORF-2 level increased in both types of cells, which may dilute the real influence
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between glial cells and LINE-1 activation. To solve this problem, we could use another
marker of glial cells in a future study. For example, S100β is another specific marker for
mature astrocytes. We could use S100β to further confirm if LINE-1 increases in astrocytes
after binge METH. Because METH causes activation of gliosis in the striatum, cortex, and
hippocampus [55, 56] and we also observed increased ORF-2 immunofluorescence colocalizing with GFAP immunofluorescence in both the SGZ and SVZ, it is possible that
METH-induced LINE-1 activation without subsequent retrotransposition may be
associated with gliosis.
Enhanced gliogenesis is another reason for the observation of increased GFAP.
Gliogenesis is the generation of glial cells from progenitors and precursor cells. Dr.
Mandyam’s group observed that intermittent 1 hour access to METH (I-ShA) and
voluntary exercise increased gliogenesis in the medial prefrontal cortex [164]. They
discussed that an I-ShA-induced proliferative environment may be attributable to changes
in endogenous levels of neurotransmitters in the medial prefrontal cortex, especially DA,
in which activation of distinct DA receptors have been pro-proliferative [165]. The
voluntary exercise-induced pro-proliferative environment is possibly attributable to
changes in vasculature and increased expression of endogenous growth factors that
promote proliferation [166]. However, this possibility is not likely as exercise is associated
with neuroprotection.
4.3. The Role of LINE-1 in the Neurogenic Zones
LINE-1 is typically quiescent in most somatic cell types. Its retrotransposition
continues to generate both intra-individual and inter-individual genetic diversity. LINE-1
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activation is strongly associated with disease development [167]. In developing neurons,
LINE-1 can express and retrotranspose at a high frequency [168], but its function in mature
neurons is unknown.
We used cleaved caspase-3 as a marker of middle-stage apoptosis and cleaved
PARP as a marker of late apoptosis. We found both signals increased in the brain tissue at
24 hours after binge METH. METH has already been documented to have a negative
impact on SVZ stem/progenitor cells, for example inducing cell death and inhibiting
neurogenesis [135]. Moreover, METH self-administration was reported to cause
hippocampal apoptosis at a proper dosage [134].
Our result shows that the ORF-2 signal co-localizes with some, but not all, apoptotic
markers within the neurogenic zones after METH treatment. This begs the question of
whether METH-induced increase of LINE-1 is in fact not associated with apoptosis. It is
too early to make this conclusion. First of all, cleaved caspase-3 and cleaved PARP are
the markers of caspase-dependent apoptosis. In reality, not only caspases, but also
calpains [169], cathepsins [170], endonucleases, and other proteases can execute
programmed cell death. Several models of caspase-independent cell death have been
described. Moreover, various cell death routes may overlap and different characteristics
may be displayed at the same time [171]. It is possible that a METH-induced increase of
LINE-1 is associated with caspase dependent and independent cell death apoptosis. To
investigate this hypothesis, we could use markers of caspase-independent apoptosis to
stain brain tissue and quantify the co-localization of the markers and ORF-2. Secondly,
the time point is another thing to be considered. Cadet’s group found that METH
treatment in immortalized rat striatal cells (M213) can caused an increase of cleavages of
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caspase-3 and PARP. They also reported that initial cleavage of caspase-3 and PARP
were detected at 8 hours post METH exposure. Additionally, both caspase-3 and PARP
were almost completely cleaved after 16 and 24 hours post METH exposure [172].
Cadet’s group showed the time course of caspase-3 activation in the striatum using
Western blot analysis (pooled protein samples from 5–6 mice per group were used) [87].
They found that caspase-3 was cleaved as early as 8 hours after treatment by
amphetamine (10 mg/kg, 4 times, every 2 hours). On the other hand, the appearance of
TUNEL-positive cells was first seen at three days after drug administration. Both in vivo
and in vitro studies indicate that our METH application model is appropriate to detect
apoptosis.
Since we detected the apoptosis at 24 hours after METH injection. It is highly
possible that the cells within neurogenic zones undergo apoptosis at different points of time.
There are two potential solutions to fix this problem. One is adding markers for different
stages of apoptosis. For example, annexin V-FITC is a common marker to specifically
detect an early-to-medium stage of apoptosis while propidium iodide (PI) can detect the
late stage of apoptosis. The other potential solution is to conduct some in vitro studies; for
example, we can artificially induce cellular apoptosis and thereby ensure that all the cells
undergo apoptosis at the same time. Further to that, we can quantify the co-localization
between apoptosis markers and ORF-2. However, the co-localization of ORF-2 and
apoptosis markers is not sufficient to conclude that a METH-induced increase of LINE-1
is associated with apoptosis. In order to study the function of LINE-1, further studies are
necessary, for example, we could investigate whether suppressing or over-expressing
LINE-1 could influence the level of apoptosis.
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Interestingly, we found that signals of cleaved caspase-3 in the SVZ and SGZ were
in the nucleus, while most papers presented cytoplasmic staining of cleaved caspase-3. To
explain this, first of all, we tested our caspase-3 antibody in PC12 cells undergoing stress
and we were able to obtain the image of clear cytoplasmic staining. Therefore, our antibody
was deemed reliable and it was shown that METH treatment can increase cleaved caspase3 in the nucleus in the SVZ and SGZ. In agreement with our result, there is another paper
that showed cleaved caspase-3 in the nucleus [103]. In that study, the authors detected cell
death in the ventricular (VZ)/SVZ of the slice culture which was from a 19-week-old
human fetus after five days in vitro culture. It is possible that cleaved caspase-3 migrates
from the cytoplasm into the nucleus 24 hours after METH exposure. In order to test the
hypothesis, more in vitro cell studies are required to determine the time course of the
migration of cleaved caspase-3 from the cytoplasm into the nucleus. Based on the literature,
caspase-3 is thought to be an essential molecule involved in the nuclear morphological
changes occurring in apoptotic cells. Moreover, many nuclear substrates for caspase-3 have
been identified despite the cytoplasmic localization of procaspase-3. Therefore, whether
cleaved caspase-3 localizes in the nucleus, and how cleaved caspase-3 has access to its
nuclear targets, are important and unresolved questions. There is a study indicating that the
translocation of cleaved caspase-3 from the cytoplasm into the nucleus is associated with
substrate-like protein(s) during progression of apoptosis [173].
In addition to the concern of the staining pattern of cleave caspase-3, cleaved PARP
staining also showed unusual pattern in the SVZ. We observed cleaved PARP staining in
the cytoplasm instead of the nucleus. The previous study indicated that the PARP family
is divided into three separate groups: 1) PARP1, PARPb (short PARP1), PARP2, and
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PARP3, 2) PARP4 and 3) Tankyrase-1, tankyrase-2a, and its isoform tankyrase-2b (also
known as PARP5 and PARP6a/b) [174]. PARP1 and 2 are considered to be nuclear
enzymes and are commonly found in the nuclei of cells. In contrast, tankyrases and PARP3
are found in both the nucleus and cytoplasm [175]. At the same time, our data also showed
that most of this cytoplasmic cleaved PARP staining is located at the edge of the SVZ,
where the epidermal cells are.
We further checked whether METH induced increases in OFR-2 is associated with
oxidative stress. We found that GSH increased at 24 hours after binge METH. Dr.
Moszczynska examined the influence of binge METH (4×20 mg/kg every 5 hours) and
chronic daily (20 mg/kg per day for 10 days) administration of METH on the level of total
glutathione in the brain. The result suggested that binge METH treatment was associated
with a regionally specific reduction of glutathione in the striatum at three hours after the
last dose of METH, however, chronic METH administration did not induce a reduction of
glutathione [66]. It was found that acute administration of METH (5 and 15 mg/kg) resulted
in production of oxidative stress as demonstrated by decreased glutathione levels in the rat
striatum and prefrontal cortex[77]. There are other studies that showed that an increased
GSH level in the brain was observed in METH abusers which was thought to be a protective
response to counteract the excessive oxidative stress induced by METH [78]. There is also
a report that demonstrated that exposure to ionizing radiation, which can cause oxidative
stress, can induce a rapid but transient decrease of the intracellular level of GSH in the
brain [79]. Chronic stressors (e.g. restraint, social stress) have been associated with a
significant reduction of cortical GSH or a reduction of GSH in the whole brain [176, 177].
Furthermore, it has been reported that administration of corticosterone (10 mg/kg)
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significantly decreased the glutathione peroxidase (GSPx) in the hippocampus [178], and
the levels of the reduced and oxidized forms of GSH in hippocampal cultures [179]. These
studies further support the association between chronic stress and decreased antioxidants.
Therefore, the decrease of antioxidant capacity in the brain may be responsible for the
stress-related oxidative damage. As demonstrated in Chapter 1, METH can cause oxidative
stress by elevating DA and GLU levels in the striatum and hippocampus [144, 180].
Increased ROS can adversely affect DNA, lipids, and cellular proteins, respectively
resulting in nucleotide oxidation, lipid peroxidation or protein nitration in the striatum and
hippocampus [144, 181]. The level of GSH, which plays a main role during antioxidant
defense, will increase under mild oxidative stress but decrease under severe oxidative stress,
such as METH administration (4×20 mg/kg) [66]. In the case of our study, we used low
dosage of METH (4×10 mg/kg) and had a longer recovery time after the last injection (24h
vs. 3h in the previous study), which may have led to the increased level of GSH. In
conclusion, both the length of recovery time and dosage of METH affect GSH level. It is
possible that chronic stress or a high dose administration of METH (4×20 mg/kg every 5
h) caused a GSH decrease due to its overutilization in the striatum, while binge METH
(4×10 mg/kg, 24h) induced less oxidative stress, leading to an increased level of GSH in
the hippocampus.
We also found that after METH treatment, ORF-2 co-localized with oxidative stress
marker GSH in most of cells within the neurogenic zones. This result indicated that METHinduced increased LINE-1 may be associated with the responses to oxidative stress. This
conclusion is supported by the previous study which reported the activation of LINE-1
induced by oxidative stress [182-184]. Wongpaiboonwattana’s group found that the
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methylation level of LINE-1 significantly decreased in H2O2-treated cells determined via
PCR. This result indicated that oxidative stress can trigger LINE-1 activation [182].
Gross’s group concluded that a decrease of LINE-1 methylation was associated with the
increased oxidative stress in both healthy and bladder cancer subjects across the various
tissue types [183]. Giorgi’s group treated neuroblastoma cells with hydrogen peroxide and
subjected them to an in vitro retrotransposition assay involving an episomal LINE-1(RP).
Their results indicated that hydrogen peroxide treatment induces an increase of
retrotransposition of the transiently transfected LINE-1(RP) as well as an increase of the
endogenous LINE-1 transcripts. Therefore, they concluded that oxidative stress can cause
LINE-1 dysregulation [184]. Kloypan’s group treated bladder cancer cells (UM-UC-3 and
TCCSUP) and human kidney cells (HK-2) with 20 μM H2O2 for 72 hours to induce
oxidative stress. Their finding suggested that the ROS exposure in cells can activate
glutathione synthesis via the transsulfuration pathway leading to a deficiency of Hcy. The
lack of Hcy can consequently cause SAM depletion and eventual hypomethylation of
LINE-1 [185]. As demonstrated in chapter 1, LINE-1 are DNA sequences which can
change their position within the genome. While undergoing retrotransposition, two open
reading frames transcribe to RNA and translate to ORF-1 and ORF-2 proteins. These two
proteins perform LINE-1 retrotransposition [98-101]. In addition to this function, ORF-1
protein is distinctive in forming large cytoplasmic foci, which are identified as cytoplasmic
stress granules (LINE-1 ORF1 Protein Localizes in Stress Granules with Other RNABinding Proteins, Including Components of RNA Interference RNA-Induced Silencing
Complex). The function of stress granules includes protection of RNA from harmful
conditions, thus their appearance under stress is a protective response [186]. That could
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potentially be the reason why we observe increased co-localization between ORF-2 and
GSH after METH administration.
One topic necessary for future consideration is whether GSH is the appropriate
marker to test oxidative stress. As demonstrated in Chapter 1, total GSH exists as free form
or bound to proteinsin cells. The relationship between GSH and ROS is a dynamic balance
process that underpins reduction/oxidation (redox) regulation and signaling. Since
glutathione reductase, which can revert free glutathione from its oxidized form (GSSG), is
constitutively active and inducible upon oxidative stress, free glutathione exists almost
exclusively in its reduced form. The ratio of reduced to oxidized glutathione within cells is
often used as a marker of oxidative stress [187-190]. To test the relationship between
oxidative stress and increased LINE-1 after METH administration, a study to determine
the ratio of GSH to GSSG is necessary. Moreover, the suppression or overexpression of
LINE-1 in the cells or animal could serve as models to investigate this relationship.
In summary, we have determined that OFR-2 increased in mature neurons and
GFAP-positive cells after METH treatment. To determine whether binge METH induced
upregulation of ORF-2 in mature neurons and glia, triple staining study for ORF-2,
GSH:GSSG and GFAP (or NeuN) may be required.
4.4. Interpretation of the co-localization results
We used the Pearson correlation coefficient (PCC) to determine the correlation of
two fluorescence channels and consequently determine the co-localization of signals from
the two channels [191]. This is a well-established method to determine correlation, and
has a range of +1 (perfect correlation) to −1 (perfect but negative correlation) with 0
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denoting the absence of a relationship. Its application to the measurement of co-localization
between fluorophores is relatively recent [192]. The PCC also has some drawbacks. It is
not sensitive to differences in signal intensity between the components of an image caused
by different labeling with fluorochromes, photobleaching, or different settings of
amplifiers, and the negative values of the correlation coefficient are difficult to interpret
when the degree of overlap is the quantity to be measured [191]. In our case, OFR-2 showed
cytoplasmic staining while NeuN, Ki-67, and cleaved PARP staining were located in the
nucleus. The PCC cannot paint the whole picture because the two stainings in which we
are interested (e.g. ORF2/NeuN, ORF2/Ki-67) do not actually co-occur. Stereology-based
counting of cells co-expressing two fluorophores in different cellular compartments is
warranted.
4.5. Conclusions and Future Directions
Our results suggest that systemic administration of neurotoxic doses of binge
METH increases the activity of LINE-1 in GFAP-positive cells and postmitotic neuronal
cells as well as in cells with increased GSH in the neurogenic zones. Binge METH can
induce increased activity of LINE-1 in the neurogenic zones which may not be associated
with apoptotic cell death but may be associated with responses to oxidative stress.
As mentioned before, we exclusively evaluated the apoptosis status at 24 hours
after METH injection. It is highly possible that the cells within neurogenic zones undergo
apoptosis at different time points, therefore, to better investigate the apoptosis status of
cells after METH treatment, a in vivo time course is required. In future, to determine the
relation between LINE1 and METH induced apoptosis, different apoptotic markers (e.g.
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annexinV-FITC) should be used. In addition, a time course study in PC12 cells after the
exposure of METH should be conducted to study the relationship between METH-induced
apoptosis and the activation and nucleus translocation of cleaved caspase-3. Moreover, a
study to determine the ratio of GSH:GSSG in the zones of interest after binge METH will
be valuable. Last but not least, studies to investigate the functional link between LINE-1
and oxidative stress in METH neurotoxicity and to determine LINE-1 function in glial cells
would be worth performing and would help to explain our results.
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ABSTRACT
THE ROLE OF LINE-1 TRANSPOSABLE ELEMENT IN
METHAMPHETAMINE NEUROTOXICITY IN THE NEUROGENIC ZONES
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Methamphetamine (METH) is a widely abused psychostimulant, which
can cause neurotoxicity in the striatum and hippocampus. Several epigenetic
changes were identified after binge METH exposure, including histone
modification, DNA methylation, and changes in miRNA levels. We have
shown that binge METH increases expression and activity of Long
INterspersed Element (LINE-1), a transposable element, in doublecortinpositive neurons within rat neurogenic zones. The goal of the present study
was to identify which type(s) of cells show increases in LINE-1 following
binge METH exposure, and determine whether binge METH-induced
increases in LINE-1 are associated with cell death. To achieve this goal, male
adult Sprague Dawley rats were treated with binge METH (4x 10mg/kg, i.p.
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every 2 h) or saline, sacrificed 24 hours later, and examined for LINE-1
expression and either markers of cell types in neurogenic zones or signs of
apoptosis within the neurogenic zones. We found that increased LINE-1
expression co-localized with most GFAP-positive cells in both the
subgranular zone (SGZ) and subventricular zone (SVZ), as well as most
NeuN-positive cells in SGZ. We also found that LINE-1 expression colocalized with some, but not all, apoptotic marker expression within the
neurogenic zones. However, LINE-1 expression did co-localize with an
oxidative stress marker. Collectively, our data suggest that systemic
administration of neurotoxic doses of binge METH increases the activity of
LINE-1 mostly in glial cells and post-mitotic cells, and may be associated
with responses to oxidative stress and/or gliosis. Supported by NIH/NIDA
R01 DA034783
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